Seaport Therapeutics

SPTX · Nasdaq Filing snapshot

Seaport Therapeutics is a clinical-stage neuroscience company developing medicines for depression, anxiety and other neuropsychiatric disorders — founded by the team behind Karuna Therapeutics. Its lead candidate, GlyphAllo (SPT-300), is an oral prodrug of allopregnanolone for major depressive disorder. The company has not generated revenue. Its $18.00 Nasdaq IPO raised about $255M gross. The filing names Sage Therapeutics — developing the same molecule — as the most direct rival, alongside marketed drugs from Janssen (Caplyta, Spravato), AbbVie (Vraylar), Takeda/Lundbeck (Trintellix), Axsome (Auvelity) and Otsuka (Rexulti), plus emerging players like Xenon and Cybin.

Listed

May 01, 2026

Raised

$255M

Sector

Biotechnology · Neuroscience · Psychiatry

Named rivals

11 in the S-1

Named in the S-1 11 named

Seaport Therapeutics

SPTX · the filer

Sage Therapeutics

named 7×

Janssen

named 1×

AbbVie

named 1×

Takeda

named 1×

Lundbeck

named 1×

Axsome

named 1×

Otsuka

named 1×

Gedeon Richter

named 1×

Xenon Pharmaceuticals

named 1×

Alto Neuroscience

named 1×

Cybin

named 1×

“

The read

Its lead drug GlyphAllo is an oral allopregnanolone prodrug — putting it head-to-head with Sage Therapeutics (same molecule class, named 7×), plus the marketed depression field: J&J's Caplyta and Spravato, AbbVie's Vraylar, Axsome's Auvelity, Otsuka's Rexulti. Founded by the Karuna Therapeutics team. No revenue yet.

Want the full picture on Seaport Therapeutics?

Request the deep Exposure Report — share-of-presence, a 90-day signal timeline, and the white space these 11 rivals leave open. We build it within 48 hours.

Request full coverage